| 摘要 |
Disclosed herein are bicyclic N-aryldiazaspiro compounds of formula (1), bridged analogs of N-heteroaryl diazaspirocyclic compounds and pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification. The aryl group can be a five or six-membered heterocyclic ring (heteroaryl). These compounds and their compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly those disorders characterized by dysfunction of nicotinic choligernic neurotransmission, including disorders involving neuromodulation of neurotransmitter release, such as dopamine release. CNS disorders, which are characterized by an alteration in normal neurotransmitter release, are another example of disorders that can be treated and/or prevented. The compounds and compositions can also be used to alleviate pain. The compounds can: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects and (iii) when employed in effective amounts, not result in appreciable adverse side effects (e.g. side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle).
|
